tetano
Editor, Senior Moderator
Eur J Med Res
. 2022 Feb 22;27(1):26.
doi: 10.1186/s40001-022-00647-6.
Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review
Jingwei Li[SUP] 1 [/SUP], Yali Wang[SUP] 1 [/SUP], Yong Liu[SUP] 2 3 [/SUP], Ziqu Zhang[SUP] 1 [/SUP], Yuyun Zhai[SUP] 1 [/SUP], Yan Dai[SUP] 4 [/SUP], Zijian Wu[SUP] 5 [/SUP], Xiang Nie[SUP] 4 [/SUP], Lunfei Du[SUP] 4 [/SUP]
Affiliations
Abstract
Objective: To determine the effect of polymorphisms and mutations in angiotensin-converting enzyme 2 (ACE2) and Type 2 transmembrane serine proteases (TMPRSS2) genes on susceptibility to corona virus disease 2019 (COVID-19) and patient prognosis.
Introduction: From December 2019 to the current time, an outbreak of epidemic of COVID-19, characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occurred around the world. It is now clear that SARS-CoV-2 binds to human ACE2 receptors, with expression of these receptors correlated with the rate of SARS-CoV-2 infection and mortality. Polymorphisms in individual patient factors, such as ACE2 and TMPRSS2 genes have been linked with an increase in negative outcomes, although evidence to affirm remains debatable.
Methods: Here, we performed a systematic review, based on guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, with the aim of assessing whether polymorphisms in ACE2 and TMPRSS2 genes affect the COVID-19 condition. We extensively searched PubMed, MEDLINE, Embase, the Cochrane Library, and Web of Science databases, for relevant articles and reports published in English between December 2019 and December 2021.
Results: A total of 495 full-text articles were downloaded, of which 185 were excluded after preliminary examination as they were duplicates. Finally, 310 articles were evaluated, by reading their titles and abstracts, and 208 of them eliminated based on our selection criteria. Finally, 33 articles met our inclusion criteria and were included in the final assessment. Genetic data from 33,923 patients with COVID-19 drawn from the general population and deriving from over 160 regions and 50 countries, as well as approximately 560,000 samples from global-public genetic databases, were included in our analysis. Ultimately, we identified 10 SNPs and 21 mutations in the ACE2 gene, along with 13 SNPs and 12 variants in the TMPRSS2 gene, which may be associated with COVID-19.
Conclusions: ACE2 and TMPRSS2 play vital roles in the onset, development, and prognosis of SARS-CoV-2 infection, and have both been strongly associated with vulnerability, intensity, and the clinical result of COVID-19. Overall, these genetic factors may have potential for future development of personalized drugs and vaccines against COVID-19.
Trial registration: CRD42021239400 in PROSPERO 2021.
Keywords: ACE2; COVID-19; Genetic susceptibility; SARS-CoV-2; TMPRSS2.
. 2022 Feb 22;27(1):26.
doi: 10.1186/s40001-022-00647-6.
Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review
Jingwei Li[SUP] 1 [/SUP], Yali Wang[SUP] 1 [/SUP], Yong Liu[SUP] 2 3 [/SUP], Ziqu Zhang[SUP] 1 [/SUP], Yuyun Zhai[SUP] 1 [/SUP], Yan Dai[SUP] 4 [/SUP], Zijian Wu[SUP] 5 [/SUP], Xiang Nie[SUP] 4 [/SUP], Lunfei Du[SUP] 4 [/SUP]
Affiliations
- PMID: 35193695
- DOI: 10.1186/s40001-022-00647-6
Abstract
Objective: To determine the effect of polymorphisms and mutations in angiotensin-converting enzyme 2 (ACE2) and Type 2 transmembrane serine proteases (TMPRSS2) genes on susceptibility to corona virus disease 2019 (COVID-19) and patient prognosis.
Introduction: From December 2019 to the current time, an outbreak of epidemic of COVID-19, characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occurred around the world. It is now clear that SARS-CoV-2 binds to human ACE2 receptors, with expression of these receptors correlated with the rate of SARS-CoV-2 infection and mortality. Polymorphisms in individual patient factors, such as ACE2 and TMPRSS2 genes have been linked with an increase in negative outcomes, although evidence to affirm remains debatable.
Methods: Here, we performed a systematic review, based on guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, with the aim of assessing whether polymorphisms in ACE2 and TMPRSS2 genes affect the COVID-19 condition. We extensively searched PubMed, MEDLINE, Embase, the Cochrane Library, and Web of Science databases, for relevant articles and reports published in English between December 2019 and December 2021.
Results: A total of 495 full-text articles were downloaded, of which 185 were excluded after preliminary examination as they were duplicates. Finally, 310 articles were evaluated, by reading their titles and abstracts, and 208 of them eliminated based on our selection criteria. Finally, 33 articles met our inclusion criteria and were included in the final assessment. Genetic data from 33,923 patients with COVID-19 drawn from the general population and deriving from over 160 regions and 50 countries, as well as approximately 560,000 samples from global-public genetic databases, were included in our analysis. Ultimately, we identified 10 SNPs and 21 mutations in the ACE2 gene, along with 13 SNPs and 12 variants in the TMPRSS2 gene, which may be associated with COVID-19.
Conclusions: ACE2 and TMPRSS2 play vital roles in the onset, development, and prognosis of SARS-CoV-2 infection, and have both been strongly associated with vulnerability, intensity, and the clinical result of COVID-19. Overall, these genetic factors may have potential for future development of personalized drugs and vaccines against COVID-19.
Trial registration: CRD42021239400 in PROSPERO 2021.
Keywords: ACE2; COVID-19; Genetic susceptibility; SARS-CoV-2; TMPRSS2.